001     119439
005     20240228145438.0
024 7 _ |a 10.1038/srep41271
|2 doi
024 7 _ |a pmid:28117398
|2 pmid
024 7 _ |a pmc:PMC5259766
|2 pmc
024 7 _ |a altmetric:15853553
|2 altmetric
037 _ _ |a DKFZ-2017-00181
041 _ _ |a eng
082 _ _ |a 000
100 1 _ |a Lanz, Tobias
|0 P:(DE-He78)22a10e47ef85d2b98a12b21a7f332e56
|b 0
|e First author
|u dkfz
245 _ _ |a Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.
260 _ _ |a London
|c 2017
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660813278_27718
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The catabolism of tryptophan to immunosuppressive and neuroactive kynurenines is a key metabolic pathway regulating immune responses and neurotoxicity. The rate-limiting step is controlled by indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO). IDO is expressed in antigen presenting cells during immune reactions, hepatic TDO regulates blood homeostasis of tryptophan and neuronal TDO influences neurogenesis. While the role of IDO has been described in multiple immunological settings, little is known about TDO's effects on the immune system. TDO-deficiency is neuroprotective in C. elegans and Drosophila by increasing tryptophan and specific kynurenines. Here we have determined the role of TDO in autoimmunity and neurodegeneration in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. We created reporter-TDO mice for in vivo imaging to show that hepatic but not CNS TDO expression is activated during EAE. TDO deficiency did not influence myelin-specific T cells, leukocyte infiltration into the CNS, demyelination and disease activity. TDO-deficiency protected from neuronal loss in the spinal cord but not in the optic nerves. While this protection did not translate to an improved overt clinical outcome, our data suggest that spatially distinct neuroprotection is conserved in mammals and support TDO as a potential target for treatment of diseases associated with neurodegeneration.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Williams, Sarah K
|b 1
700 1 _ |a Stojic, Aleksandar
|b 2
700 1 _ |a Iwantscheff, Simeon
|b 3
700 1 _ |a Sonner, Jana
|0 P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b
|b 4
|u dkfz
700 1 _ |a Grabitz, Carl
|b 5
700 1 _ |a Becker, Simon
|0 P:(DE-He78)a7dd606f37ce122c7f1c4140e754d515
|b 6
|u dkfz
700 1 _ |a Böhler, Laura-Inés
|0 P:(DE-He78)1afad4d0b5b6ef348b8fdcd72739b278
|b 7
|u dkfz
700 1 _ |a Mohapatra, Soumya Ranjan
|0 P:(DE-He78)0a6d2d4e161256f6ce1ca4b630bcf246
|b 8
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 9
|u dkfz
700 1 _ |a Küblbeck, Günter
|0 P:(DE-He78)b8759faaf3e907bcd8b6a34983994a3c
|b 10
|u dkfz
700 1 _ |a Nakamura, Toshikazu
|b 11
700 1 _ |a Funakoshi, Hiroshi
|b 12
700 1 _ |a Opitz, Christiane
|0 P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34
|b 13
|u dkfz
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 14
|u dkfz
700 1 _ |a Diem, Ricarda
|0 P:(DE-He78)0b1c40947becd495c5aa9778ef098ef4
|b 15
|u dkfz
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.1038/srep41271
|g Vol. 7, p. 41271 -
|0 PERI:(DE-600)2615211-3
|p 41271 -
|t Scientific reports
|v 7
|y 2017
|x 2045-2322
909 C O |p VDB
|o oai:inrepo02.dkfz.de:119439
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)22a10e47ef85d2b98a12b21a7f332e56
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)1f1efec9a95d1778031cb6f0b19ba58b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)a7dd606f37ce122c7f1c4140e754d515
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)1afad4d0b5b6ef348b8fdcd72739b278
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)0a6d2d4e161256f6ce1ca4b630bcf246
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)b8759faaf3e907bcd8b6a34983994a3c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)0b1c40947becd495c5aa9778ef098ef4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Translational cancer research
|x 0
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b SCI REP-UK : 2015
920 1 _ |0 I:(DE-He78)G160-20160331
|k G160
|l Neuroimmunologie und Hirntumorimmunologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
920 1 _ |0 I:(DE-He78)G161-20160331
|k G161
|l Brain Cancer Metabolism
|x 2
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 3
920 1 _ |0 I:(DE-He78)D110-20160331
|k D110
|l D110 Zelluläre Immunologie
|x 4
920 1 _ |0 I:(DE-He78)G370-20160331
|k G370
|l KKE Neuroonkologie
|x 5
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G160-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)G161-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)D110-20160331
980 _ _ |a I:(DE-He78)G370-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21